Jeff KnoxJan 114 minWhy We InvestedWhy We Invested - Via ScientficBy Matt Fates, Partner and Jeff Knox, Associate Summary The last two decades have seen tremendous expansion of biological datasets and...
Team InnosparkOct 17, 20231 minCEO SpotlightCEO Spotlight - Luca Giani of Ilios TherapeuticsMeet Luca Giani, CEO of Ilios Therapeutics, a biopharmaceutical company discovering and developing rationally-designed multi-targeted...
Jeff KnoxAug 8, 20234 minWhy We InvestedWhy We Invested - Persist.AISummary In drug development, new molecular entities get all the press. That’s largely justified – new molecules mean new medicines and...